ArticleFrontiers in medicine2025
Predictive value of a severity-of-illness score for toxic epidermal necrolysis (SCORTEN) factors for in-hospital mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- SCORTEN in Contrast: Two Cases of SJS/TEN Overlap With Divergent Outcomes Highlighting the Role of Renal Dysfunction.Clinical case reports · 2026Article
- Article
- Severe Cutaneous Adverse Reactions Associated With Newer-Generation Antiseizure Medications: A Real-World Pharmacovigilance Study Based on FAERS and JADER.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening mucocutaneous reactions with high mortality. The A severity-of-illness score for toxic epidermal necrolysis (SCORTEN) scale remains the principal tool for early estimation of in-hospital death risk. The study was aimed to assess the predictive value of individual SCORTEN components for hospital mortality in a real-world Moscow cohort and to characterize demographic and etiologic factors associated with outcome. Methods: We retrospectively reviewed 150 adult patients (median age 50 years; IQR: 31-63; 59.3% female) admitted with SJS (45.3%) or TEN (54.7%) between 2019 and 2024. SCORTEN parameters were recorded within 24 h of admission. Univariate analyses (chi-square or Fisher's exact test) identified associations between each SCORTEN variable and in-hospital death. Kaplan-Meier survival curves and Cox proportional-hazards models quantified time-to-event outcomes and adjusted hazard ratios (HR). Results: Overall mortality was 18.7% ( Discussion: These findings support continued use of SCORTEN while highlighting the need to recalibrate or augment its parameters-particularly renal and oncologic variables-to improve risk stratification in current therapeutic contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.